Also Known As: Pimozide, Orap
Pimozide (Orap) is an antipsychotic drug of the diphenylbutylpiperidine class. It was discovered at Janssen Pharmaceutica in 1963. It has a high potency compared to chlorpromazine (ratio 50-70:1). On a weight basis it is even more potent than haloperidol. It also has special neurologic indications for Tourette syndrome and resistant tics. The side effects include akathisia, tardive dyskinesia, and, more rarely, neuroleptic malignant syndrome and prolongation of the QT interval.
Pimozide is used in its oral preparation in schizophrenia and chronic psychosis (on-label indications in Europe only), Tourette syndrome and resistant tics (Europe, USA and Canada). In Germany the 1 mg tablet is indicated for the treatment of some forms of reactive depression.
Pimozide has been used in the treatment of delusional disorder and paranoid personality disorder.
It has been used for delusions of parasitosis.
Use as a Listeria monocytogenes inhibitor has been described.